Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data

Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data

Show other versions (1)

Introduction and Objectives: Atrial fibrillation (AF) is the most common form of arrhythmia worldwide and a significant health burden. Edoxaban, a recent novel oral anticoagulant (NOAC), is being investigated in the European real-world ETNA-AF study of patients with non-valvular atrial fibrillation...

Full description

Bibliographic Details
Main Author: Pedro Monteiro
Format: Article
Language:English
Published: Elsevier 2020-11-01
Series:Revista Portuguesa de Cardiologia (English Edition)
Subjects:
Fibrilhação auricular
Edoxabano
Baseline
Vida real
Online Access:http://www.sciencedirect.com/science/article/pii/S2174204920303883

Internet

http://www.sciencedirect.com/science/article/pii/S2174204920303883

Similar Items